X4 Pharmaceuticals, Inc
For the period ended Sep 30, 2026. Filed Nov 4, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 4, 2026
XFOR$3.25-2.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited)
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(In thousands, except share and per share amounts)
(unaudited)
| Three Months Ended September 30, | Nine Months Ended September 30, | |||
|---|---|---|---|---|
| 2026 | 2025 | 2026 | 2025 | |
| License and other revenue | $106 | $199 | $6,778 | $28,293 |
| Product revenue, net | 2,773 | 1,566 | 7,615 | 4,252 |
| Total revenue | 2,879 | 1,765 | 14,393 | 32,545 |
| Costs and operating expenses: | ||||
| Cost of revenue | 513 | 351 | 2,728 | 5,393 |
| Research and development | 13,343 | 17,337 | 43,872 | 54,202 |
| General and administrative | 9,014 | 11,586 | 24,481 | 36,134 |
| Total operating expenses | 22,870 | 29,274 | 71,081 | 95,729 |
| Loss from operations | (19,991) | (27,509) | (56,688) | (63,184) |
| Other (expense) income, net: | ||||
| Interest income | 1,821 | 901 | 5,905 | 2,591 |
| Interest expense | (2,194) | (2,257) | (6,492) | (6,690) |
| Change in fair value of warrant liability | 340 | (676) | 948 | 12,796 |
| Other income, net | (171) | (304) | (264) | (746) |
| Total other (expense) income, net | (204) | (2,336) | 97 | 7,951 |
| Loss before provision for income taxes | (20,195) | (29,845) | (56,591) | (55,233) |
| Provision for income taxes | 3 | (30) | 5 | 41 |
| Net loss | $(20,198) | $(29,815) | $(56,596) | $(55,274) |
| Net loss per share: basic and diluted | $(0.16) | $(0.69) | $(0.45) | $(2.87) |
| Weighted average shares outstanding: basic and diluted | 126,523,631 | 43,272,773 | 126,326,320 | 19,242,848 |
| Other comprehensive loss, net of tax: | ||||
| Net loss | $(20,198) | $(29,815) | $(56,596) | $(55,274) |
| Reclassification of accumulated currency translation adjustment due to substantial liquidation of foreign subsidiary | 119 | — | 119 | — |
| Change in net unrealized gains on marketable debt securities | 4 | 20 | (10) | 4 |
| Comprehensive loss | $(20,075) | $(29,795) | $(56,487) | $(55,270) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.